- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06055920
PEERLESS II 연구
PEERLESS II: 폐색전증에서 FlowTriever와 항응고제 단독의 RCT
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Aarhus, 덴마크, 8200
- Aarhus University Hospital
-
-
-
-
-
Augsburg, 독일
- University Hospital Augsburg
-
Bad Krozingen, 독일
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin, 독일
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin, 독일
- Unfall Krankenhaus Berlin
-
Cologne, 독일
- University Hospital Cologne
-
Dresden, 독일
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf, 독일
- Universitaetsklinikum Dὒsseldorf
-
Essen, 독일
- Universitaetsklinikum Essen
-
Essen, 독일
- Elisabeth Hospital GmbH
-
Frankfurt, 독일
- CCB Frankfurt
-
Hamburg, 독일
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, 독일
- University Hospital - Heidelberg
-
Kaiserslautern, 독일
- Westpfalz Klinikum
-
Munich, 독일
- Klinikum rechts der Isar (TUM)
-
Munich, 독일
- Ludwig Maximilians-University
-
Regensburg, 독일
- University Hospital Regensburg
-
Villingen-Schwenningen, 독일
- Schwarzwald-Baar-Klinikum
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35243
- Brookwood Medical Center
-
Birmingham, Alabama, 미국, 35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena, California, 미국, 91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06520
- Yale University
-
-
Florida
-
Largo, Florida, 미국, 33770
- HCA FL Largo Medical Center
-
Orlando, Florida, 미국, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern University
-
-
Michigan
-
Lansing, Michigan, 미국, 48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, 미국, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden, New Jersey, 미국, 08103
- Virtua Health
-
-
New York
-
Buffalo, New York, 미국, 14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York, New York, 미국, 10075
- Northwell Health
-
Rochester, New York, 미국, 14642
- University of Rochester Medical Center
-
Stony Brook, New York, 미국, 11794
- Stony Brook University Hospital
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, 미국, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, 미국, 43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, 미국, 18015
- St. Luke's University Hospital
-
Erie, Pennsylvania, 미국, 16507
- UPMC Hamot
-
Erie, Pennsylvania, 미국, 16505
- AHN Saint Vincent Hospital
-
Harrisburg, Pennsylvania, 미국, 17101
- UPMC Harrisburg
-
Philadelphia, Pennsylvania, 미국, 19144
- Thomas Jefferson University
-
Philadelphia, Pennsylvania, 미국, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- UPMC Heart and Vascular Institute
-
Pittsburgh, Pennsylvania, 미국, 15212
- Allegheny Health Network Research Institute
-
York, Pennsylvania, 미국, 17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood, Tennessee, 미국, 37027
- HCA Tristar
-
Knoxville, Tennessee, 미국, 37920
- UTMC Knoxville
-
Nashville, Tennessee, 미국, 37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas, Texas, 미국, 75235
- Parkland Hospital
-
Fort Worth, Texas, 미국, 76104
- Texas Health Harris Methodist Hospital
-
San Antonio, Texas, 미국, 78229
- Methodist Main Hospital
-
Temple, Texas, 미국, 76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042
- Inova Fairfax
-
-
West Virginia
-
Charleston, West Virginia, 미국, 25304
- Charleston Area Medical Center
-
Morgantown, West Virginia, 미국, 26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53215
- Aurora Saint Luke's Medical Center
-
-
-
-
-
Aalst, 벨기에
- Onze Lieve Vrouwziekenhuis
-
-
-
-
-
Basel, 스위스
- Universitaetsspital Basel
-
Bern, 스위스
- Universitätsspital Bern
-
Lucerne, 스위스
- Luzerner Kantonsspital
-
-
-
-
-
Madrid, 스페인
- Hopital Clinico Universitario San Carlos
-
-
-
-
British Columbia
-
New Westminster, British Columbia, 캐나다, V3L 3W7
- Royal Columbian Hospital
-
Surrey, British Columbia, 캐나다, V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Lille, 프랑스
- CHU Lille
-
Lyon, 프랑스
- Hôpital Louis Pradel
-
Marseille, 프랑스
- Hôpital Nord Marseille
-
Marseille, 프랑스
- AP-HM Hopital La Timone
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
활성 비교기: Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
기간: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
모든 원인 및 PE 관련 사망률
기간: 30일 및 90일
|
30일 및 90일
|
|
|
모든 원인 및 PE 관련 재입원
기간: 30일 및 90일
|
30일 및 90일
|
|
|
도보 6분 거리
기간: 1개월 방문시
|
1개월 방문시
|
|
|
RV/LV 비율
기간: 48시간 방문 시
|
48시간 방문 시
|
|
|
사후 PE 손상 진단(PPEI)
기간: 3개월간의 방문을 통해
|
3개월간의 방문을 통해
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
기간: up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
기간: Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
기간: Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
기간: At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
기간: At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
기간: At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
기간: At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Jay Giri, MD, Penn Medicine
- 수석 연구원: Bernhard Gebauer, MD, Charité University Hospital Berlin
- 수석 연구원: Felix Mahfoud, MD, Universitaetsspital Basel
- 수석 연구원: Frances Mae West, MD, Jefferson Health
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .